Naslov
Pentadecapeptide BPC 157 therapy in rats having occlusion of the inferior mesenteric vein as well as inferior mesenteric vein occlusion and colon-colon anastomosis

Autori
Đuzel, Antonija ; Gojković, Slaven ; Krezić, Ivan ; Žižek, Helena ; Vraneš, Hrvoje ; Simonji, Karol ; Lovrić, Eva ; Knežević, Mario ; Škrtić, Anita ; Boban Blagaić, Alenka ; Seiwerth, Sven ; Sikirić, Predrag

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Gastroenterology (New York, N.Y. 1943), 160 (2021), 6(S) / - , 2021, S-232

Skup
Digestive Disease Week

Mjesto i datum
Online; konferencija, 21.05.2021. - 23.05.2021

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
BPC 157 ; colon-colon anastomosis ; vessel occlusion

Sažetak
Aim. Stable gastric pentadecapeptide BPC 157 may be the therapy in rats having occlusion of the inferior mesenteric vein (IMV) as well as IMV occlusion and colon-colon (C-C) anastomosis. Recently, BPC 157 administration, by rapid activation of the collateral vessel pathways, rapidly reversed major venous occlusion syndromes, inferior caval vein syndrome, Pringle maneuver, ischemia, reperfusion and Budd- Chiari syndrome (Vascul Pharmacol 2018, World J Hepatol 2020, World J Gastrointest Pathophysiol 2020), portal and caval hypertension and aortal hypotension. Thereby, BPC 157 may resolve in rats having occluded IMV, the consequent intracranial (superior sagittal sinus), portal and caval hypertension, and aortal hypertension, organ lesions (gastrointestinal, liver, kidney, lung, heart and brain) along with recovering of the failed anastomosis healing. Methods. Rats having IMV ligation (close to inflow to superior mesenteric vein (SMV)) and C-C anastomosis (made at the middle part of descending colon) received (/kg) BPC 157 (10μg, 10ng) or saline (5ml) as an abdominal bath immediately after vein ligation or anastomosis formation, and thereafter, per-orally in drinking water till the sacrifice. Results. IMV occlusion immediately induced (i.e., at 24h) intracranial hypertension (22±2 mmHg in superior sagittal sinus), portal (31±4 mmHg) and caval (17±3 mmHg) hypertension and aortal hypotension (69±3 mmHg), which were permanent. Likewise, congested were IMV and SMV and their tributaries, and weak biomechanical capacity of anastomosis was not more than 1 ml of the applied water without leaking. Microscopically, at 24h occlusion-time, without therapy, we noted the severe transmural hemorrhage and inflammation in anastomosis, transmural hyperemia in all GItract, reduced villi in intestinal mucosa and reduced crypt with focal denudation of superficial epithelia s as well as large bowel dilatation, focal thickening of the alveolar membranes, lung congestion, pulmonary edema and moderate intra- alveolar hemorrhage, mild degeneration of proximal tubules, severe vascular congestion and mild interstitial edema in kidney, mild activation of Kupffer cells and severe enlargement of sinusoids with liver congestion, moderate myocardium congestion, brain edema and neural damage. Contrarily, BPC 157 rats administration (i.e., 10ng) largely attenuated these disturbances (i.e., microscopically, only mild lung congestion, and mild anastomosis hemorrhage). Markedly were counteracted (intracranial hypertension (-5±2 mmHg in superior sagittal sinus), portal (13±4 mmHg) and caval (9±3 mmHg) hypertension and aortal hypotension (97±3 mmHg), failed anastomosis biomechanic (more than 5 ml water without leaking), and venous congestion through middle colic vein (MCV)-SMV pathway (Fig). Conclusion. BPC 157’s beneficial effect recovered IMV occlusion-disturbances.

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti

POVEZANOST RADA